This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morosini, M.-I.
Right arrow Articles by Baquero, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morosini, M.-I.
Right arrow Articles by Baquero, F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2001, p. 2427-2431, Vol. 45, No. 9
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.9.2427-2431.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

In Vitro Activity of Telithromycin against Spanish Streptococcus pneumoniae Isolates with Characterized Macrolide Resistance Mechanisms

María-Isabel Morosini, Rafael Cantón,* Elena Loza, María-Cristina Negri, Juan-Carlos Galán, Felisa Almaraz, and Fernando Baquero

Servicio de Microbiología, Hospital Ramón y Cajal, Madrid, Spain

Received 22 December 2000/Returned for modification 1 February 2001/Accepted 24 May 2001

The susceptibilities to telithromycin of 203 Streptococcus pneumoniae isolates prospectively collected during 1999 and 2000 from 14 different geographical areas in Spain were tested and compared with those to erythromycin A, clindamycin, quinupristin-dalfopristin, penicillin G, cefotaxime, and levofloxacin. Telithromycin was active against 98.9% of isolates (MICs, <= 0.5 µg/ml), with MICs at which 90% of isolates are inhibited being 0.06 µg/ml, irrespective of the resistance genotype. The corresponding values for erythromycin were 61.0% (MICs, <= 0.25 µg/ml) and >64 µg/ml. The erm(B) gene (macrolide-lincosamide-streptogramin B resistance phenotype) was detected in 36.4% (n = 74) of the isolates, which corresponded to 93.6% of erythromycin-intermediate and -resistant isolates, whereas the mef(A) gene (M phenotype [resistance to erythromycin and susceptibility to clindamycin and spiramycin without blunting]) was present in only 2.4% (n = 5) of the isolates. One of the latter isolates also carried erm(B). Interestingly, in one isolate for which the erythromycin MIC was 2 µg/ml, none of these resistance genes could be detected. Erythromycin MICs for S. pneumoniae erm(B)-positive isolates were higher (range, 0.5 to >64 µg/ml) than those for erm(B)- and mef(A)-negative isolates (range, 0.008 to 2 µg/ml). The corresponding values for telithromycin were lower for both groups, with ranges of 0.004 to 1 and 0.002 to 0.06 µg/ml, respectively. The erythromycin MIC was high for a large number of erm(B)-positive isolates, but the telithromycin MIC was low for these isolates. These results indicate the potential usefulness of telithromycin for the treatment of infections caused by erythromycin-susceptible and -resistant S. pneumoniae isolates when macrolides are indicated.

* Corresponding author. Mailing address: Servicio de Microbiología, Hospital Ramón y Cajal, 28034-Madrid, Spain. Phone: 34-91-3368330. Fax: 34-91-3368809. E-mail: rcanton{at}hrc.insalud.es.

Antimicrobial Agents and Chemotherapy, September 2001, p. 2427-2431, Vol. 45, No. 9
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.9.2427-2431.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • de la Pedrosa, E. G. G., Morosini, M.-I., van der Linden, M., Ruiz-Garbajosa, P., Galan, J. C., Baquero, F., Reinert, R. R., Canton, R. (2008). Polyclonal Population Structure of Streptococcus pneumoniae Isolates in Spain Carrying mef and mef plus erm(B). Antimicrob. Agents Chemother. 52: 1964-1969 [Abstract] [Full Text]  
  • Rantala, M., Haanpera-Heikkinen, M., Lindgren, M., Seppala, H., Huovinen, P., Jalava, J., the Finnish Study Group for Antimicrobial Resistan, (2006). Streptococcus pneumoniae Isolates Resistant to Telithromycin.. Antimicrob. Agents Chemother. 50: 1855-1858 [Abstract] [Full Text]  
  • Rantala, M., Huikko, S., Huovinen, P., Jalava, J., the Finnish Study Group for Antimicrobial Resistan, (2005). Prevalence and Molecular Genetics of Macrolide Resistance among Streptococcus pneumoniae Isolates Collected in Finland in 2002. Antimicrob. Agents Chemother. 49: 4180-4184 [Abstract] [Full Text]  
  • Canton, R., Mazzariol, A., Morosini, M.-I., Baquero, F., Cornaglia, G. (2005). Telithromycin activity is reduced by efflux in Streptococcus pyogenes. J Antimicrob Chemother 55: 489-495 [Abstract] [Full Text]  
  • Tiemei, Z., Xiangqun, F., Youning, L. (2004). Resistance Phenotypes and Genotypes of Erythromycin-Resistant Streptococcus pneumoniae Isolates in Beijing and Shenyang, China. Antimicrob. Agents Chemother. 48: 4040-4041 [Abstract] [Full Text]  
  • Shi, J., Montay, G., Chapel, S., Hardy, P., Barrett, J. S., Sack, M., Marbury, T., Swan, S. K., Vargas, R., Leclerc, V., Leroy, B., Bhargava, V. O. (2004). Pharmacokinetics and Safety of the Ketolide Telithromycin in Patients with Renal Impairment. J Clin Pharmacol 44: 234-244 [Abstract] [Full Text]  
  • Morosini, M.-I., Loza, E., del Campo, R., Almaraz, F., Baquero, F., Canton, R. (2003). Fluoroquinolone-Resistant Streptococcus pneumoniae in Spain: Activities of Garenoxacin against Clinical Isolates Including Strains with Altered Topoisomerases. Antimicrob. Agents Chemother. 47: 2692-2695 [Abstract] [Full Text]  
  • Bingen, E., Doit, C., Loukil, C., Brahimi, N., Bidet, P., Deforche, D., Geslin, P. (2003). Activity of Telithromycin against Penicillin-Resistant Streptococcus pneumoniae Isolates Recovered from French Children with Invasive and Noninvasive Infections. Antimicrob. Agents Chemother. 47: 2345-2347 [Abstract] [Full Text]  
  • Morosini, M.-I., Canton, R., Loza, E., del Campo, R., Almaraz, F., Baquero, F. (2003). Streptococcus pyogenes isolates with characterized macrolide resistance mechanisms in Spain: in vitro activities of telithromycin and cethromycin. J Antimicrob Chemother 52: 50-55 [Abstract] [Full Text]  
  • Ackermann, G., Rodloff, A. C. (2003). Drugs of the 21st century: telithromycin (HMR 3647)--the first ketolide. J Antimicrob Chemother 51: 497-511 [Abstract] [Full Text]  
  • Low, D. E., de Azavedo, J., Weiss, K., Mazzulli, T., Kuhn, M., Church, D., Forward, K., Zhanel, G., Simor, A., McGeer, A. (2002). Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob. Agents Chemother. 46: 1295-1301 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»